Biogen posts Q3 2026 earnings beat and lifts FY EPS outlook
Biogen reported third‑quarter 2026 revenue of about $2.8 billion, up roughly 11% year over year. The company posted a GAAP loss of $20.6 million but delivered non‑GAAP earnings per share of $2.62, surpassing analyst expectations. Growth‑portfolio sales climbed 49% to $1.26 billion, driven by the first full quarter of contributions from the Apellis acquisition. Biogen subsequently increased the lower bound of its full‑year 2026 non‑GAAP EPS guidance to a range of $12.20‑$13.00.
Why it matters
The company said the higher guidance reflects the strength of its Growth Portfolio and integration of Apellis products, suggesting better profitability than previously forecast. Investors will see an upward revision to the EPS target for the year, which may support the stock price.
Key facts
- 1Third‑quarter 2026 revenue was $2.804 billion, an 11% increase from $2.535 billion a year earlier. quiverquant.com
- 2GAAP net loss attributable to Biogen was $20.6 million, or a loss of $0.14 per diluted share. quiverquant.com
- 3Non‑GAAP diluted earnings per share for the quarter were $2.62. tradingview.com
- 4Growth Portfolio revenue reached $1.26 billion, up 49% year over year. quiverquant.com
- 5Biogen expanded its full‑year 2026 reported non‑GAAP diluted EPS guidance to $12.20‑$13.00. quiverquant.com
- 6Cash and cash equivalents at quarter end were approximately $1.3 billion, with total debt of about $7.7 billion. quiverquant.com
Summary written by AlphAI AI Desk from 11 of 11 sources. Not investment advice. Figures are as stated by the linked sources.